Cargando…
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective
Epithelial ovarian cancer (EOC) has a poor prognosis. Since the introduction of paclitaxel as antineoplastic agent >20 years ago, only a few phase III randomized trials have shown challenging data regarding different therapeutic options for facing its aggressive clinical course and granting activ...
Autores principales: | Loizzi, Vera, Ranieri, Girolamo, Laforgia, Mariarita, Gadaleta, Cosmo Damiano, Gargano, Giulio, Kardhashi, Anila, De Liso, Maria, Naglieri, Emanuele, Del Vecchio, Vittoria, Cicinelli, Ettore, Cormio, Gennaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439101/ https://www.ncbi.nlm.nih.gov/pubmed/32831909 http://dx.doi.org/10.3892/ol.2020.11951 |
Ejemplares similares
-
Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer
por: Loizzi, Vera, et al.
Publicado: (2017) -
A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients
por: Loizzi, Vera, et al.
Publicado: (2022) -
Mitochondrial Dysfunctions in Type I Endometrial Carcinoma: Exploring Their Role in Oncogenesis and Tumor Progression
por: Musicco, Clara, et al.
Publicado: (2018) -
Paget disease of the vulva an analysis of 24 cases
por: Loiacono, Rosalia Maria Rita, et al.
Publicado: (2019) -
The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication
por: De Nola, Rosalba, et al.
Publicado: (2019)